Provectus Pharmaceuticals Inc. is a development-stage biopharmaceutical study focused on oncology and dermatology therapies. The company recently announced that the results of its phase II trial showed comparable trends to phase I survival data for 20 subjects with metastatic melanoma.

The one-year overall survival data of its lead oncology agent PV-10 showed longer overall and disease specific survival for subjects that were responsive to the agent, relative to those who did not experience a robust response. In addition, several subjects experienced spontaneous regression of untreated tumors after PV-10 treatment of other tumors.

The company also announced that Professor John F. Thompson, MD, professor of melanoma and surgical oncology at the University of Sydney, director of the Melanoma Institute Australia, and lead investigator of the phase II study of PV-10 for Metastatic Melanoma, recently presented the study results at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany.

Provectus Pharmaceuticals, Inc.

(Public, OTC:PVCT)

StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer, one of the largest target markets worldwide and seeking “compassionate use” in Australia and USA, look for Provectus to make a splash within the next couple of months.

They are developing and testing one of the most exciting anti- cancer compounds. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) announced that they have commenced recruitment for their Phase 2 clinical trial of the company’s lead oncology agent PV-10 at a fifth major center, now covering the northeastern United States. The new center joins the other company’s centers located in Sydney, Brisbane and Adelaide, Australia, and Houston, Texas.

Sanjiv Agarwala, M.D. has been appointed as the principal investigator at the new center, located at St. Luke’s Hospital & Health Network, in Bethlehem, PA. Over the next several months, the company intends to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States.

Phase 2 clinical testing of PV-10 is designed to assess the agent as a treatment for Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study will

Provectus Pharmaceuticals Inc. (PVCT.OB) is a company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive, and more economical than conventional therapies. The company has also developed a number of intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.

Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs — PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for moderate to severe psoriasis and for atopic dermatitis. The company has received orphan drug designation from the FDA for PV-10.

Provectus announced that on September 10th 2008 CEO Craig Dees, Ph.D. will present at the Wall Street Analyst Forum 19th Annual Analyst Conference. Mr. Dees will review the results of the Phase 1 clinical trial Provectus has completed in melanoma patients. In this study, individual tumors were injected with PV-10, and in many cases the tumors began